

# CRITCARE BITES

## NON-INVASIVE MODES OF VENTILATION: NIV, HFNC

*Clare Fong*  
*Alexandra Hospital, National University Hospital*



M A D F O R M E D I C I N E



# INTRODUCTION

## NON-INVASIVE MODES OF VENTILATION

CPAP

BiPAP  
'NIV'

HFNC

## RESPIRATORY FAILURE

AHRF

*Acute hypoxemic respiratory failure*

HYPERCAPNIC



## BENEFITS OF NON-INVASIVE MODES

- Spontaneous ventilation is maintained
- Preserves physiological pathways of airway protection
- Reduces complications related to endotracheal intubation and IMV
  - VILI
  - VAP
  - Sedation, neuromuscular blockade
- Prevents diaphragmatic atrophy
- Maintains normal heart-lung interactions



## POTENTIAL HARMS

- Hypoxemia, dysregulated inspiratory effort, altered respiratory mechanics and inhomogeneous lung inflation → vicious cycle
- Intense inspiratory effort results in high tidal volumes and tachypnea
- Injured lungs are exposed to a higher risk of volutrauma and barotrauma
  - P-SILI
  - Large swings in transpulmonary pressure
  - Pendelluft phenomenon
- May account for increased mortality when NIV or HFNC fails
- Delay in endotracheal intubation




# NIV

- Patient triggered, pressure-targeted mode of ventilation
- Positive inspiratory pressure is delivered above a PEEP
- Reduces work of breathing, improves V/Q matching
- Beneficial effects on the left heart
- Hypoventilation and respiratory acidosis best treated with NIV
- For pure AHRF, effect of positive inspiratory pressure needs to be monitored to ensure that it does not lead to excessive tidal volumes: predicts subsequent failure




# BIPAP VS CPAP

- BIPAP
  - IPAP  $\approx$  PIP on the ventilator
  - EPAP  $\approx$  PEEP
    - Affects oxygenation
  - 'Driving pressure' = IPAP – PEEP
    - Influences VT and thus ventilation
- CPAP
  - $\approx$  PEEP
    - Affects oxygenation
- Titrate FiO<sub>2</sub> according to need



# INTERFACE

- Oronasal face mask
  - Problems: leak, pressure sores and discomfort
- Helmet
  - No pressure on skin, allowing for more prolonged use of NIV
  - Problems: claustrophobia, higher levels of PEEP to avoid collapse of the hood in patients with large tidal volumes, high gas flows necessary to avoid CO<sub>2</sub> re-breathing
  - Meta-analysis, helmet NIV > face mask and HFNC in reducing risk of endotracheal intubation and mortality (Ferreyro et al, JAMA 2020)



# INDICATIONS: PREVENTING INTUBATION

Strong	Moderate, 'think twice'	Avoid, insufficient evidence
<b>COPD exacerbation</b> Reduces intubation and mortality	Neuromuscular weakness <i>Ability to protect airway, bulbar weakness</i>	Asthma
<b>APO</b> Reduces intubation, maybe CPAP > NIV	Chest wall deformity and kyphoscoliosis	ARDS
OSA/OHS	Post-operative respiratory failure <i>Post-abdominal surgery, post-CABG</i> Reduces intubation	Pneumonia
Bronchiectasis	Extubation failure only COPD Does not prevent intubation, increased mortality	Upper airway obstruction
Mild-moderate AHRF <i>PF ratio &gt; 150</i> Including immunocompromised Reduces intubation vs conventional O2	Bronchoscopy	All other extubation failure
	Palliation	





# INDICATIONS: PREVENTING INTUBATION

Strong	Moderate, 'think twice'	Avoid, insufficient evidence
<b>COPD exacerbation</b> Reduces intubation and mortality	Neuromuscular weakness <i>Ability to protect airway, bulbar weakness</i>	Asthma
<b>APO</b> Reduces intubation. maybe CPAP > NIV	Chest wall deformity and <i>hypercoagulable</i>	ARDS

- Consider closer monitoring in ICU/ HD especially when initiating NIV in patients for indications with only moderate level of support and in patients with mild-moderate AHRF
- Low threshold to declare NIV failure and proceed to intubation

<b>Extubation failure only COPD</b> Does not prevent intubation, increased mortality	<b>Upper airway obstruction</b>
<b>Mild-moderate AHRF</b> <i>PF ratio &gt; 150</i> <i>Including immunocompromised</i> Reduces intubation vs conventional O2	<b>Bronchoscopy</b>
	<b>All other extubation failure</b>
	<b>Palliation</b>






# INDICATIONS: PRE-OXYGENATION

- Strongly consider in the **obese** and those with **AHRF**

ORIGINAL ARTICLE



## Noninvasive Ventilation for Preoxygenation during Emergency Intubation

**Authors:** Kevin W. Gibbs, M.D. , Matthew W. Semler, M.D., Brian E. Driver, M.D. , Kevin P. Seitz, M.D., Susan B. Stempek, P.A., Caleb Taylor, M.D., M.P.H., Daniel Resnick-Ault, M.D., , for the PREOXI Investigators and the Pragmatic Critical Care Research Group\* [Author Info & Affiliations](#)

Published June 13, 2024 | N Engl J Med 2024;390:2165-2177 | DOI: 10.1056/NEJMoa2313680 | [VOL. 390 NO. 23](#)

- Critically ill adults (age  $\geq 18$  years) undergoing tracheal intubation: preoxygenation with either noninvasive ventilation or an oxygen mask
- Primary outcome: hypoxemia – SpO<sub>2</sub> <85% between induction of anesthesia and 2 minutes after tracheal intubation
- Hypoxemia 9.1% in the noninvasive-ventilation group vs 18.5% in oxygen-mask group



# INDICATIONS: WEANING

- **Hasten extubation in COPD patients**
  - Failed SBT but otherwise ready to be weaned
- **Post-extubation to prevent re-intubation**
  - High risk patients (varies between studies)
    - **COPD**
    - **Heart failure**
    - **Age >65**
    - Previous extubation failure
    - Hypercapnia ( $\text{PaCO}_2 > 45\text{mmHg}$  before or after SBT)
    - Obesity, OHS



# CONTRAINDICATIONS

- Cardiac/ respiratory arrest
- Severe hemodynamic instability
- Severe metabolic acidosis
- Severe respiratory acidosis e.g. pH <7.20 (can still consider in COPD)
- Multi-organ failure
- Active hemoptysis/ hematemesis
- Facial surgery or trauma
- Depressed GCS <8
- Inability to protect airway



# INITIAL SETTINGS AND ADJUSTMENTS

- Spontaneous/ timed mode
- IPAP: start at 10cmH<sub>2</sub>O, titrate in increments of 2, maximum of 24cmH<sub>2</sub>O
  - COPD ~16-18cmH<sub>2</sub>O
  - Neuromuscular weakness ~10-12cmH<sub>2</sub>O
  - AHRF most <16cmH<sub>2</sub>O
  - IPAP rise time: 0.1s
- EPAP: start at 5cmH<sub>2</sub>O, titrate in increments of 2, maximum of 10-12cmH<sub>2</sub>O
- Monitor the 'driving pressure' (IPAP – EPAP)/ tidal volumes as settings are adjusted:
- Titrate FiO<sub>2</sub> to target SpO<sub>2</sub> (usually 88-92%)
- Set RR at 12 breaths/min (usually as a 'back up' as patients are spontaneously breathing)
- Monitor ABG for changes in pH, pCO<sub>2</sub> and pO<sub>2</sub>



## WHERE TO SITE PATIENT?

- Intensive care unit (ICU)
  - High risk of failure and subsequent intubation: non-COPD indication or pH <7.20
- High dependency unit (HD)
  - NIV likely to be successful: COPD patient with pH  $\geq 7.20$  and comfortable
- Respiratory General Ward
  - DNR patients
  - Sustained improvement on NIV




# PREDICTING NIV FAILURE

- ABG 1 hour after initiation
  - No improvement or decrease in pH
  - Minimal or no improvement in PF ratio: <200 after 1h increased risk of intubation, <150 increased risk of death
- Persistent tachypnea
- High tidal volumes
  - Tidal volume of >9-9.5ml/kg of predicted body weight 1h after NIV initiation associated with increased risk of intubation and death
- HACOR score
  - Components: pH, HR, RR, P/F ratio, GCS
  - Score of >5 predicts failure
  - At 1 hour of NIV, odds ratio of NIV failure is 1.73 for every 1-point increase in HACOR score
- Consider the original indication for NIV
  - NIV failure rates in COPD ~15-20%
  - NIV failure rates for AHRF ~40-60% → lower threshold to abandon NIV and proceed for intubation
    - NIV failure independent predictor for death in such patients



# HFNC

- Generates a flow-dependent  $\text{FiO}_2$
- Delivers flow higher or equal to inspiratory requirement and thereby, diminishes air entrainment
- Gas goes through an air-oxygen blender that can generate a total flow of up to 60L/min is heated and humidified with an active humidifier






# AIR ENTRAINMENT

## Oxygen Dilution

- $FiO_2 = 0.21 + 0.04 \times \text{L/min of oxygen}$ 
  - $FiO_2 \text{ on 4LNP: } 0.21 + 0.04 \times 4 = 0.37$
- NOT TRUE
- Concentration of oxygen that patients inspire depends on the ventilatory minute volume (MV) and the flow rate of oxygen



If there is a NC at 6 liter/min delivering 45%, but your patient is breathing 20 liter/min at room air (21%), then what %  $FiO_2$  do you think is actually reaching the patients trachea? I don't actually know but definitely NOT 45% and likely closer to 21%. This phenomenon is known as oxygen dilution and will occur if you don't meet or exceed your patients inspiratory flow demands.



# PHYSIOLOGY

- Reduces entrainment of air by utilizing high flow
  - Air entrainment occurs when patient's intrinsic flow rate exceeds that of O<sub>2</sub> flow rate
  - Heated and humidified air allows patients to tolerate high flow rates
- High flow washes out CO<sub>2</sub> in anatomical dead space
- PEEP
  - Low levels 5-8cmH<sub>2</sub>O at higher flows
  - Mechanical splinting of nasopharynx



- FIO<sub>2</sub> levels higher and more stable than conventional O<sub>2</sub>
- Reduction in dead space → reduction in work of breathing
- Better V/Q matching as PEEP allows for alveolar recruitment



# INDICATIONS

- Acute hypoxemic respiratory failure with PF ratio  $\leq 200$ 
  - Consider especially in immunocompromised patients
- To prevent re-intubation in certain circumstances
  - Select patients who passed SBT but PF ratio  $< 200$  mmHg
  - High risk patients
    - Elderly, heart failure, COPD
  - Post-cardiac surgery (to prevent re-intubation)



# INDICATIONS: AHRF

**Table 2 Main clinical studies on HFNCO in adults with hypoxemic acute respiratory failure**

References	Study design	Population	Patients (N)	Main results
Hypoxemic ARF in the ICU				
[7]	Cohort, unselected patients. HFNCO 50 L/min vs face mask oxygen	Hypoxemic ARF	38	Improved oxygenation Decreased respiratory rate
[20]	Cohort, unselected patients. HFNCO 20–30 L/min vs face mask oxygen	Hypoxemic ARF	20	Improved oxygenation Decrease in respiratory/heart rates, dyspnea, respiratory distress, and thoracoabdominal asynchrony
[12]	HFNCO vs face mask oxygen	Hypoxemic ARF	60	Decreased treatment failure (defined as need for non-invasive ventilation) from 30 to 10 %. Fewer desaturation episodes
[6]	Cohort study, HFNCO 20–30 L/min vs face mask oxygen	Hypoxemic ARF	20	Improved comfort; improved oxygenation
[26]	Cohort study (post hoc)	Hypoxemic ARF (2009 A/H1N1v outbreak)	20	9/20 (45 %) success (no intubation). All 8 patients on vasopressors required intubation within 24 h. After 6 h of HFNCO, non-responders had lower PaO <sub>2</sub> /FiO <sub>2</sub> values
[24]	Observational, single-center study	ARDS	45	40 % intubation rate. HFNCO failure associated with higher SAPS II, development of additional organ failure, and trends toward lower PaO <sub>2</sub> /FiO <sub>2</sub> values and higher respiratory rate
[22]	Multicenter, open-label RCT with 3 groups: HFNCO, usual oxygen therapy (face mask), or non-invasive ventilation	Hypoxemic ARF, PaO <sub>2</sub> /FiO <sub>2</sub> ≤300	310	Intubation rate was 38 % with HFNCO, 47 % with standard oxygen, and 50 % with non-invasive ventilation. Decreased 90-day mortality with HFNCO
[83]	Retrospective before/after study of HFNCO	Hypoxemic ARF	172	Reduced need for intubation (100 vs 63 %, <i>p</i> < 0.01)
[28]	Patients intubated after HFNCO	Hypoxemic ARF	175	In patients intubated early, lower mortality (39.2 vs 66.7 %), higher extubation success (37.7 vs 15.6 %), and more ventilator-free days. Early intubation was associated with decreased ICU mortality
Hypoxemic ARF in the emergency department				
[21]	Patients with ARF (>9 L/min oxygen or clinical signs of respiratory distress)	Hypoxemic ARF	17	Decreased dyspnea and respiratory rate and improved oxygenation
[84]	RCT of HFNCO vs standard oxygen for 1 h	Hypoxemic ARF	40	Decreased dyspnea and improved comfort

ARF acute respiratory failure, HFNCO high-flow nasal cannula oxygenation, RCT randomized controlled trial

FLORALI



# INDICATIONS: AHRF

**Table 2 Main clinical studies on HFNCO in adults with hypoxemic acute respiratory failure**

References	Study design	Population	Patients (N)	Main results
Hypoxemic ARF in the ICU				
[7]	Cohort, unselected patients. HFNCO 50 L/min vs face mask oxygen	Hypoxemic ARF	38	Improved oxygenation Decreased respiratory rate
[20]	Cohort, unselected patients. HFNCO 20–30 L/min vs face mask oxygen	Hypoxemic ARF	20	Improved oxygenation Decrease in respiratory/heart rates, dyspnea, respiratory dis-

- Reduces endotracheal intubation compared to conventional O<sub>2</sub>
- Reduces intubation over NIV in moderate-severe AHRF where PF ratio <200
- FLORALI and subsequent meta-analysis in JAMA 2020: reduced mortality compared to conventional O<sub>2</sub>
- Immunocompromised patients
  - Post-hoc analysis of FLORALI
  - Included patients: hematological or solid organ cancer, drug-induced, steroids, HIV
  - Intubation rates higher in patients with NIV vs HFNC

Hypoxemic ARF in the emergency department				
[21]	Patients with ARF (>9 L/min oxygen or clinical signs of respiratory distress)	Hypoxemic ARF	17	Decreased dyspnea and respiratory rate and improved oxygenation
[84]	RCT of HFNCO vs standard oxygen for 1 h	Hypoxemic ARF	40	Decreased dyspnea and improved comfort

ARF acute respiratory failure, HFNCO high-flow nasal cannula oxygenation, RCT randomized controlled trial

higher extubation success (37.7% vs 15.8%), and more ventilator-free days. Early intubation was associated with decreased ICU mortality



# INDICATIONS: POST-EXTUBATION

- Reduces re-intubation rates post-extubation in respiratory failure
  - Compared to conventional O<sub>2</sub>
- Both high and low risk patients
- Non-inferior to NIV
- Alternating between NIV and HFNC may be better than HFNC alone

**Effect of Postextubation High-Flow Nasal Cannula  
vs Conventional Oxygen Therapy on Reintubation  
in Low-Risk Patients  
A Randomized Clinical Trial**

Gonzalo Hernández, MD, PhD; Concepción Vaquero, MD; Paloma González, MD; Carles Subira, MD; Fernando Frutos-Vivar, MD; Gemma Rialp, MD; Cesar Laborda, MD; Laura Colinas, MD; Rafael Cuenca, MD; Rafael Fernández, MD, PhD

JAMA | **Original Investigation** | **CARING FOR THE CRITICALLY ILL PATIENT**

**Effect of Postextubation High-Flow Nasal Cannula  
vs Noninvasive Ventilation on Reintubation  
and Postextubation Respiratory Failure in High-Risk Patients  
A Randomized Clinical Trial**

Gonzalo Hernández, MD, PhD; Concepción Vaquero, MD; Laura Colinas, MD; Rafael Cuenca, MD; Paloma González, MD; Alfonso Canabal, MD, PhD; Susana Sanchez, MD; Maria Luisa Rodríguez, MD; Ana Villasclaras, MD; Rafael Fernández, MD, PhD



# CONTRAINDICATIONS

- Cardiac/ respiratory arrest
- Severe hemodynamic instability
- Severe metabolic acidosis
- Multi-organ failure
- Hypercapnic respiratory failure
- Active hemoptysis/ hematemesis/ epistaxis
- Severe encephalopathy
- Base of skull fracture or recent surgery to the nose



# PREDICTING HFNC FAILURE

- SpO<sub>2</sub> <90% or RR ≥30 on >70/70
- Development of copious tracheal secretions
- Lack of improvement in signs of high respiratory-muscle workload
- **ROX index**
  - SpO<sub>2</sub>/FiO<sub>2</sub> to RR
    - ROX score ≥4.88 at 2/6/12 hours: lower risk of progressing to mechanical ventilation
    - ROX score <3.85: risk of HFNC failure is high and should consider intubating
    - ROX score 3.85 to <4.88: repeat scoring 1-2 hours later
- Acidosis with pH <7.35
- Hemodynamic instability
- Neurological deterioration





## AHRF: NIV VERSUS HFNC?

- Mild-to-moderate AHRF (PF > 150): either HFNC/ NIV/ CPAP
  - Reduces risk of endotracheal intubation compared to conventional O2 therapy
  - In the absence of shock, other contraindications
  - Helmet NIV may be superior to HFNC in COVID-19 respiratory failure (HENIVOT trial)
- Moderate-severe AHRF
  - Intubate the patient or choose HFNC over NIV (preference will still be for intubation)
  - FLORALI trial: HFNC reduced intubation and mortality over NIV in patients with PF ratio <200
  - Risk of NIV failure higher when PF ratio <150 and NIV failure independent risk factor for mortality
- Patients
  - Immunocompromised
    - Do not need to adopt a strategy that is different for immunocompetent patients
    - Based on post-hoc analysis of FLORALI trial, HFNC had mortality benefit
  - COPD, OHS, heart failure: NIV/ CPAP



## REFERENCES AND FURTHER READING

- Munshi L, Mancebo J, Brochard LJ. Noninvasive Respiratory Support for Adults with Acute Respiratory Failure. *N Engl J Med*. 2022 Nov 3;387(18):1688-1698.
- Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J*. 2017 Aug 31;50(2):1602426.
- Grieco DL, Maggiore SM, Roca O. Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS. *Intensive Care Med*. 2021 Aug;47(8):851-866.
- Keenan SP, Sinuff T, Cook DJ, Hill NS. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature. *Ann Intern Med* 2003;138:861-87
- Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. *Ann Intern Med* 2010;152:590-600.

